Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
In an email communication dated 11 April 2025, which was received by Cipla on 17 April 2025, the USFDA confirmed the VAI classification for the facility.
The official announcement was made on Thursday, 17 April 2025, after market hours.
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.
The pharma major’s consolidated net profit jumped 48.73% to Rs 1,570.51 crore in Q3 FY25 as against Rs 1,055.90 crore reported in Q3 FY24. Total revenue from operations grew by 7.10% year on year (YoY) to Rs 7,072.97 crore in the quarter ended 31 December 2024.
The counter rose 0.34% to Rs 1,520.65 on the BSE.
Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,52,80,804 comprising of 80,76,40,402 equity shares of face value Rs 2 each.
Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane® for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer (‘NSCLC') and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in H1 FY 2025-26 in the United States of America.
Cipla’s formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for the treatment of metastatic breast cancer, advanced or metastatic non-small cell lung cancer (NSCLC), and metastatic pancreatic cancer.
The product is expected to be launched in the United States of America during the first half of fiscal year 2025–26, it added.